

Danny Platform

First published: 01/02/2024

Last updated: 15/09/2025

Data source

Human

Death registry

Drug registry

Hospital inpatient records

Other

Pharmacy dispensing records

Primary care medical records

Administrative details

Administrative details

Data source ID

1111215

Data source acronym

Danny Platform

Data holder

[Sqilline Health](#)

Data source type

Death registry

Drug registry

Hospital inpatient records

Other

Pharmacy dispensing records

Primary care medical records

Data source type, other

Private and hospital laboratories, and many others

Main financial support

Funding from industry or contract research

Funding from public-private partnership

Care setting

Hospital inpatient care

Hospital outpatient care

Other

Data source qualification

If the data source has successfully undergone a formal qualification process (e.g., from the EMA, ISO or other certifications), this should be described.

Yes

Description of the qualification

ISO 9001:2015

ISO/IEC 27001:2022

Data source website

[Danny Platform](#)

Contact details

Daniel Penchev info@sqilline.com

Main

info@sqilline.com

Data source regions and languages

Data source countries

Bulgaria

Croatia

Poland

Romania

Serbia

Slovenia

Data source languages

Bulgarian

Croatian

English

Polish

Romanian

Serbian

Slovenian

Data source establishment

Data source established

01/04/2018

Data source time span

First collection: 01/04/2018

The date when data started to be collected or extracted.

Publications

Data source publications

[Familial Hypercholesterolemia identification algorithm in patients with acute cardiovascular event in a large hospital electronic database in Bulgaria – a call for implementation](#)

[Triple-negative breast cancer in Bulgaria: epidemiological data and treatment patterns based on real-world evidence and patient registries](#)

[Clinical Data Extraction and Normalization of Cyrillic Electronic Health Records Via Deep-Learning Natural Language Processing](#)

[Adequate effectiveness of ribociclib plus letrozole or fulvestrant in patients with advanced or metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer treated in routine Bulgarian clinical practice](#)

[Nationwide analysis of the breast cancer guidelines adherence in Bulgaria](#)

[Proton therapy for head and neck cancer therapy: A real-world data case study from Bulgaria](#)

[Describing Adult Heart Failure Patients – Assessment of Real-Life Data in Two Sites](#)

[Real-world effectiveness of dabrafenib and trametinib in patients with BRAF-positive melanoma treated in routine Bulgarian clinical practice](#)

Real-world evidence of first-line osimertinib effectiveness in Bulgarian patients: a retrospective analysis

A Real-World Study on Pulmonary Arterial Hypertension in Bulgaria: A Single-Center Retrospective Study From 2012 to 2022

Bulgarian exploratory analysis of time from diagnosis to treatment of lung cancer patients (BEAT): a retrospective database study on the patient pathway and time to treatment.

Incidence, patient characteristics and treatment patterns of early-stage triple-negative breast cancer (TNBC) in Bulgaria: A retrospective analysis based on real-world data

Studies

List of studies that have been conducted using the data source

Adequate effectiveness of ribociclib plus letrozole or fulvestrant in patients with advanced or metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer treated in routine Bulgarian clinical practice

Real-world effectiveness of dabrafenib and trametinib in patients with BRAF-positive melanoma treated in routine Bulgarian clinical practice

Proton therapy for head and neck cancer therapy: A real-world data case study from Bulgaria

Describing Adult Heart Failure Patients – Assessment of Real-Life Data in Two Sites

Nationwide analysis of the breast cancer guidelines adherence in Bulgaria

Real-world evidence of first-line Osimertinib effectiveness in Bulgarian patients: a retrospective analysis

A Real-World Study on Pulmonary Arterial Hypertension in Bulgaria: A Single-Center Retrospective Study From 2012 to 2022

Data elements collected

The data source contains the following information

Disease information

Does the data source collect information with a focus on a specific disease? This might be a patient registry or other similar initiatives.

Yes

Rare diseases

Are rare diseases captured? In the European Union a rare disease is one that affects no more than 5 people in 10,000.

Yes

Pregnancy and/or neonates

Does the data source collect information on pregnant women and/or neonatal subpopulation (under 28 days of age)?

Yes

Hospital admission and/or discharge

Yes

ICU admission

Is information on intensive care unit admission available?

Yes

Cause of death

Captured

Cause of death vocabulary

ICD-10

Prescriptions of medicines

Captured

Prescriptions vocabulary

ATC

Dispensing of medicines

Captured

Dispensing vocabulary

ATC

Advanced therapy medicinal products (ATMP)

Is information on advanced therapy medicinal products included? A medicinal product for human use that is either a gene therapy medicinal product, a somatic cell therapy product or a tissue engineered products as defined in Regulation (EC) No 1394/2007 [Reg (EC) No 1394/2007 Art 1(1)].

Yes

Contraception

Is information on the use of any type of contraception (oral, injectable, devices etc.) available?

No

Indication for use

Does the data source capture information on the therapeutic indication for the use of medicinal products?

Captured

Indication vocabulary

ICD-10

Medical devices

Is information on medicinal devices (e.g., pens, syringes, inhalers) available?

Yes

Administration of vaccines

No

Procedures

Does the data source capture information on procedures (e.g., diagnostic tests, therapeutic, surgical interventions)?

Captured

Procedures vocabulary

ICD-10

Healthcare provider

Is information on the person providing healthcare (e.g., physician, pharmacist, specialist) available?

The healthcare provider refers to individual health professionals or a health facility organisation licensed to provide health care diagnosis and treatment services including medication, surgery and medical devices.

Yes

Clinical measurements

Is information on clinical measurements (e.g., BMI, blood pressure, height) available?

Yes

Genetic data

Are data related to genotyping, genome sequencing available?

Captured

Biomarker data

Does the data source capture biomarker information? The term “biomarker” refers to a broad subcategory of medical signs (objective indications of medical state observed from outside the patient), which can be measured accurately and reproducibly. For example, haematological assays, infectious disease markers or metabolomic biomarkers.

Captured

Patient-reported outcomes

Is information on patient-reported outcomes (e.g., quality of life) available?

Yes

Patient-generated data

Is patient-generated information (e.g., from wearable devices) available?

No

Units of healthcare utilisation

Are units of healthcare utilisation (e.g., number of visits to GP per year, number of hospital days) available or can they be derived? Units of healthcare utilisation refer to the quantification of the use of services for the purpose of preventing or curing health problems.

Yes

Unique identifier for persons

Are patients uniquely identified in the data source?

Yes

Diagnostic codes

Captured

Diagnosis / medical event vocabulary

ICD-10

Medicinal product information

Captured

Medicinal product information collected

Active ingredient(s)

Brand name

Dosage regime

Dose

Package size

Route of administration

Strength

Medicinal product vocabulary

ATC

Quality of life measurements

Not Captured

Lifestyle factors

Captured

Lifestyle factors

Alcohol use

Tobacco use

Sociodemographic information

Captured

Sociodemographic information collected

Age

Country of origin

Education level

Gender

Quantitative descriptors

Population Qualitative Data

Population age groups

Paediatric Population (< 18 years)

Preterm newborn infants (0 - 27 days)

Term newborn infants (0 - 27 days)

Infants and toddlers (28 days - 23 months)

Children (2 to < 12 years)

Adolescents (12 to < 18 years)

Adults (18 to < 46 years)

Adults (46 to < 65 years)

Elderly (≥ 65 years)

Adults (65 to < 75 years)

Adults (75 to < 85 years)

Adults (85 years and over)

Estimated percentage of the population covered by the data source in the catchment area

70 - 80% of inpatient care in Bulgaria

95% of inpatient care in oncology in Bulgaria

Description of the population covered by the data source in the catchment area whose data are not collected (e.g., people who are registered only for private care)

For Bulgarian population - all inpatient oncology care, and more than 50% of the inpatient care in Bulgaria for the other diseases.

Family linkage

Family linkage available in the data source permanently or can be created on an ad hoc basis

Ad hoc

Population

Population size

2019472

Active population size

2017219

Population by age group

Age group	Population size	Active population size
Paediatric Population (< 18 years)	178804	176551
Preterm newborn infants (0 – 27 days)	30	30
Term newborn infants (0 – 27 days)	45	45
Infants and toddlers (28 days – 23 months)	9200	8947
Children (2 to < 12 years)	114488	113488
Adolescents (12 to < 18 years)	55041	54041
Adults (18 to < 46 years)	424955	424955
Adults (46 to < 65 years)	594933	594933
Elderly (≥ 65 years)	820780	820780
Adults (65 to < 75 years)	395419	389419
Adults (75 to < 85 years)	318995	318995
Adults (85 years and over)	106366	106366

Median observation time

Median time (years) between first and last available records for unique individuals captured in the data source

55.58

Median time (years) between first and last available records for unique active individuals (alive and currently registered) capt

53.05

Data flows and management

Biospecimen access

Are biospecimens available in the data source (e.g., tissue samples)?

No

Access to subject details

Can individual patients/practitioners/practices included in the data source be contacted?

No

Description of data collection

Automatically synchronizing EHR data with private cloud solution

Event triggering registration

Event triggering registration of a person in the data source

Disease diagnosis

Other

Start of treatment

Event triggering registration of a person in the data source, other

Laboratory examination, outpatient care, etc...

Event triggering de-registration of a person in the data source

Death

Event triggering creation of a record in the data source

Patient hospitalization or outpatient care event, laboratory examination and many others

Data source linkage

Linkage

Is the data source described created by the linkage of other data sources (prelinked data source) and/or can the data source be linked to other data source on an ad-hoc basis?

No

Data management specifications that apply for the data source

Data source refresh

Monthly

Informed consent for use of data for research

Not Required

Possibility of data validation

Can validity of the data in the data source be verified (e.g., access to original medical charts)?

Yes

Data source preservation

Are records preserved in the data source indefinitely?

Yes

Approval for publication

Is an approval needed for publishing the results of a study using the data source?

Yes

Data source last refresh

30/06/2025

Common Data Model (CDM) mapping

CDM mapping

Has the data source been converted (ETL-ed) to a common data model?

Yes

CDM Mappings

CDM name

OMOP

CDM website

<https://www.ohdsi.org/Data-standardization/>
